Report Sections

See All Reports

  • HP:0001650: Aortic valve stenosis
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001650: Aortic valve stenosis

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (5)


    Name (Synonyms) Correlation
    drug1697 Foldax Tria Aortic Valve Wiki 0.71
    drug4252 TAVR or SAVR Wiki 0.71
    drug840 COVID-19 test Wiki 0.71
    Name (Synonyms) Correlation
    drug2954 Online Questionnaire Wiki 0.50
    drug663 Blood sampling Wiki 0.50

    Correlated MeSH Terms (2)


    Name (Synonyms) Correlation
    D001024 Aortic Valve Stenosis NIH 1.00
    D003251 Constriction, Pathologic NIH 0.71

    Correlated HPO Terms (0)


    Name (Synonyms) Correlation

    Clinical Trials

    Navigate: Correlations   HPO

    There are 2 clinical trials


    1 Early Feasibility Study for the Foldax Tria Aortic Heart Valve

    The purpose of this study is to conduct the initial clinical investigation of the Foldax Polymer Aortic Valve to collect evidence on the device's safety and performance. The study is anticipated to confirm successful clinical safety and clinical effectiveness with significant improvements in clinical hemodynamic performance.

    NCT03851068
    Conditions
    1. Aortic Valve Disease
    2. Aortic Valve Stenosis
    Interventions
    1. Device: Foldax Tria Aortic Valve
    MeSH:Aortic Valve Stenosis
    HPO:Aortic valve stenosis

    Primary Outcomes

    Description: The adverse events consistent with the Objective Performance Criteria (OPC), for flexible heart valves will be compared to those rates defined as acceptable levels in the standard. a. Thromboembolism b. Valve Thrombosis c. Major Paravalvular leak d. Major Hemorrhage e. Endocarditis

    Measure: Primary Safety Endpoints: Objective Performance Criteria for Flexible Heart Valve Events Assessments

    Time: 12 months following patient enrollment completion

    Description: The rates of other events will be compared to clinical outcomes for surgically implanted heart valves reported in the literature. a. All-caused death b. Valve related death c. Valve-related reoperation d. Valve explant e. Hemorrhage f. All-cause reoperation g. Valve-related death

    Measure: Primary Safety Endpoints: Surgical Valve Events Rate Assessment

    Time: 12 months following patient enrollment completion

    Description: Hemodynamic performance parameters are mmHG mean gradient and derived Effective Orifice Area (EOA). Success is defined as clinically significant improvement in hemodynamic performance (Effective Orifice Area (EOA)) at one year based on literature reports for surgical aortic valve replacement.

    Measure: Primary Effectiveness Endpoint: Hemodynamic Performance Assessment

    Time: 12 months following patient enrollment completion

    Description: Clinically significant improvement (one grade) in the New York Heart Association (NYHA) functional classification status at 365 days compared to baseline. a. Class I - No symptoms and no limitations in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. b. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. c. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100m). Comfortable only at rest. d. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

    Measure: Primary Effectiveness Endpoint: New York Heart Association Improvement Assessment

    Time: 12 months following patient enrollment completion

    Secondary Outcomes

    Description: Assessment of patient experiencing a stroke verified by imaging and or physical exam

    Measure: Secondary Endpoints: Stroke

    Time: 5 years following patient enrollment

    Description: Assessment of patient having a TIA verified by imaging and or physical exam

    Measure: Secondary Endpoint: Transient Ischemic Attack

    Time: 5 Years following patient enrollment

    Description: Length of stay in the ICU post valve implantation defined as arrival time/date in hours and minutes to transfer to floor time/date in hours and minutes.

    Measure: Secondary Endpoint: ICU Duration of Stay

    Time: 30 days post procedure

    Description: Ventilation time in hours defined as arrival time/date in recovery in hours and minutes to date and time extubated in hours and minutes

    Measure: Secondary Endpoint: Ventilation Time

    Time: 30 Days post procedure

    Description: New/post-operative atrial fibrillation - confirmed on ECG after closure during initial or subsequent admission or at one-year review

    Measure: Secondary Endpoint: New Onset Atrial Fibrillation

    Time: 12 Months post procedure

    Description: Post procedure length of stay defined as the date and time in hours and minutes documented for arrival in the recovery unit to date and time in hours and minutes of discharge in hours and minutes.

    Measure: Secondary Endpoint: Length of Stay in Hospital

    Time: 30 days post procedure

    Description: Patient readmission to the hospital post discharge measured by date/time

    Measure: Secondary Endpoint: Readmission

    Time: 30 days post discharge

    Description: Hemolysis screen is measured by blood tests including hemoglobin and liver enzyme assessments

    Measure: Secondary Endpoint: Hemolysis screen

    Time: 12 months post procedure

    Description: Change in QOL as measured by the Kansas City Cardiomyopathy Questionnaire

    Measure: Secondary Endpoint: Change in Quality of Life (QOL)

    Time: 12 months post procedure
    2 Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis - a Collateral Effect of the SARS-CoV-2 Pandemic (AS DEFER)

    Background and Project Rationale: Degenerative aortic valve stenosis affects 2% of the elderly population aged 70 years or older and progresses insidiously with advancing age [1] before manifesting with symptoms such as decreased exercise tolerance, shortness of breath, chest pain and syncope on exertion. Without aortic valve replacement, the survival prognosis of patients with symptomatic aortic stenosis is poor. In the PARTNER 1B trial, all-cause mortality among 179 inoperable patients with severe symptomatic aortic stenosis allocated to conservative management amounted to 51% at one year [2]. Consistently, prospective registry data reported a mortality rate of 55% at 1 year in 78 patients with severe aortic stenosis undergoing conservative management [3]. The rapid spread of the SARS-CoV-2 pandemic represents an unprecedented challenge for healthcare systems. A limited number of ventilators and ICU beds call for a careful allocation of healthcare resources. On March 20 2020, the Federal Council prohibited elective interventions in all hospitals in Switzerland. Patients with untreated severe aortic stenosis are particularly vulnerable to SARS-CoV-2 infection [4] and face the dual risk of cardiac death from aortic stenosis on one side, and death from acute respiratory distress syndrome secondary to SARS-CoV-2 infection on the other. While the balance between the two risks is a matter of clinical judgement, the investigators established an algorithm for the management of patients with severe aortic stenosis during the SARS-CoV-2 pandemic. Patients with aortic stenosis deemed critical will undergo valvular replacement in spite of the ongoing pandemic while patients with severe but not critical aortic stenosis will undergo deferred intervention once the number of new SARS-CoV-2 infections flattens. In the current situation, aortic valve replacement in patients with severe, non-critical aortic stenosis will be deferred in order to give priority to SARS-CoV-2 patients. This unique situation allows the investigators to study the effect of deferral of aortic valve replacement in patients with severe aortic stenosis. The study is an amendment to the Swiss-TAVI registry. In contrast to the Swiss-TAVI registry, patients are not enrolled at the time of aortic valve replacement, but already at the time of referral for aortic valve replacement. Primary Objective: The aim of the present observational study is to explore the effect of deferral of valvular replacement in patients with severe but not critical aortic stenosis on morbidity and mortality. The primary objective is to describe rates of morbidity and mortality among patients with severe but not critical aortic stenosis in the interval from referral/indication for valvular replacement to intervention. Project Design: The study is a prospective cohort study of patients with severe aortic stenosis referred for aortic valve replacement. All referrals for aortic valve replacement will be allocated to either "transcatheter aortic valve replacement (TAVR)/ surgical aortic valve replacement (SAVR) (standard of care)" or "deferred intervention" based on prespecified criteria. Patients with critical aortic stenosis as defined by an aortic valve area (AVA) <0.6 cm2 or a transvalvular mean gradient of >60 mmHg or a history of cardiac decompensation during the previous 3 months or clinical symptoms on minimal exertion (NYHA III) will be allocated to TAVR or SAVR. All other patients with severe aortic stenosis defined by an AVA <1.0 cm2 will be scheduled for a deferred intervention.

    NCT04333875
    Conditions
    1. Aortic Valve Stenosis
    Interventions
    1. Device: TAVR or SAVR
    MeSH:Aortic Valve Stenosis Constriction, Pathologic
    HPO:Aortic valve stenosis

    Primary Outcomes

    Measure: Composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure

    Time: Assessed at 6 months after indication/referral for aortic valve replacement.

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook